BIOTELEMETRY, INC.

Operating margin

11.2%

Net margin

28.7%

Return on equity

8.1%

Return on assets

4.4%

Return on capital (ROCE)

1.9%

Liabilities / assets

46.5%

Debt / equity

0.87×

Book value / share

$10.92

Revenue growth (YoY)

10.0%

Net income growth (YoY)

−28.7%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

1.99grey zone

Accruals / assets

−5.5%clean

Piotroski F-Score

6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer changeFeb 9, 2021
• Other material eventFeb 1, 2021
• Director / officer changeJan 29, 2021
• Entered a material agreement · Amended charter or bylaws · Other material eventDec 21, 2020
• Results of operationsOct 29, 2020
• Results of operationsJul 30, 2020
• Shareholder voteMay 11, 2020
• Results of operationsMay 6, 2020

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.